Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Long-Term Deferred Tax: 2015-2020

  • Aytu Biopharma's Long-Term Deferred Tax rose 69.74% to $39.6 million in Q2 2020 from the same period last year, while for Jun 2020 it was $39.6 million, marking a year-over-year increase of 69.74%. This contributed to the annual value of $39.6 million for FY2020, which is 69.74% up from last year.
  • According to the latest figures from Q2 2020, Aytu Biopharma's Long-Term Deferred Tax is $39.6 million, which was up 69.74% from $23.3 million recorded in Q2 2019.
  • In the past 5 years, Aytu Biopharma's Long-Term Deferred Tax registered a high of $39.6 million during Q2 2020, and its lowest value of $16.7 million during Q2 2018.
  • For the 3-year period, Aytu Biopharma's Long-Term Deferred Tax averaged around $26.5 million, with its median value being $23.3 million (2019).
  • As far as peak fluctuations go, Aytu Biopharma's Long-Term Deferred Tax dropped by 13.69% in 2018, and later spiked by 69.74% in 2020.
  • Over the past 4 years, Aytu Biopharma's Long-Term Deferred Tax (Quarterly) stood at $19.4 million in 2017, then declined by 13.69% to $16.7 million in 2018, then soared by 39.38% to $23.3 million in 2019, then spiked by 69.74% to $39.6 million in 2020.
  • Its Long-Term Deferred Tax stands at $39.6 million for Q2 2020, versus $23.3 million for Q2 2019 and $16.7 million for Q2 2018.